Correlation of non-alcoholic fatty liver disease and gut microflora: clinical reports and treatment options

Abstract

AbstractA prevalent liver condition called non-alcoholic fatty liver disease (NAFLD) may progress into non-alcoholic steatohepatitis (NASH) and cause life-threatening complications like cirrhosis and liver cancer. The development and progression of NAFLD has been linked to the make-up and functioning of the gut microflora. This article reviews the clinical studies reported to investigate the connection between changes in the gut microbiota and metabolic markers in NAFLD patients. According to the study findings, dysbiosis of the gut microflora were observed in NAFLD patients, which are manifested by variations in the proportions of particular bacterial species. These changes are linked to fibrosis, liver inflammation, and metabolic abnormalities. The article also discusses various treatments targeting the gut microbiota, including dietary modifications, exercise, prebiotics, probiotics, synbiotics, antibiotics, and fecal microbiota transplantation. These therapies are intended to enhance NAFLD outcomes and reestablish the healthy gut microflora. While some studies have shown promising results, further research is needed to establish the optimal approaches, long-term safety, and efficacy of these treatments for NAFLD.